Sleep DisturbanceNCT07839312
Bonafide Sleep Supplement for Menopausal Women With Sleep Complaints
A study testing S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate in people with Sleep Disturbance, run by Bonafide Health at 1 site in United States.
Trial summary
This open-label study was designed to evaluate whether a daily dietary sleep supplement could improve sleep quality and related daytime well-being in menopausal women aged 40 to 65 with sleep complaints. Read more about this study
- Who is it for?
- Ages 40 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Sleep Disturbance
- What is being tested?
- S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 111 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Jan 2025to 1 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy women who are 40 to 65 years of age (inclusive).
- Have a body mass index (BMI) between 18.5 to 39.9 kg/m2 (inclusive).
- Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form (PROMIS SD SF) T-Score Cut Point ≥ 55 (equivalent to a raw score of 25).
- Women enrolled in this research study may be of perimenopausal, (12 or more months without a menstrual period) or post-menopausal status. Post-menopause defined as the last natural menstrual period (LNMP) completed at least 12 months prior to screening. Perimenopause defined as women who complained of irregular menstrual cycle in the past 12 months, with a forward or postponed cycle more than 7 days. At least 2 cycles were missing during the past 12 months or reported menopause for at least 60 days.
- In good general health (no uncontrolled diseases or conditions) and able to consume the study product.
- Agree to refrain from treatments listed in Section 12.4 in the defined timeframe.
- Has stable access to Wi-Fi and an iPhone or Android device.
- Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
Who cannot join
- Individuals who are lactating, pregnant, or planning to become pregnant during the study.
- Perimenopausal women who are sexually active will be required to specify contraceptive method or be excluded.
- Currently incarcerated prisoners.
- Currently enrolled in a different clinical trial.
- Use of any treatment for sleep symptoms or other concomitant treatments listed in Section 12.4.
- Participants whose insomnia is predominantly attributed to significant medical, psychiatric, or environmental factors (e.g., restless leg syndrome, sleep apnea, chronic pain, anxiety, depression, or shift work) may be excluded, at the discretion of the investigator, if it is determined that these factors could interfere with study outcomes or participant safety.
Show all 10Show fewer
- Have a known sensitivity, intolerability, or allergy to the study product or their excipients.
- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study or influence the results or the potential subject's ability to participate in the study.
- Major surgery in one month prior to screening or planned major surgery during the study.
- Any other active or unstable medical conditions or use of medications/supplements/ therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant. Note: screened participants with infections would be eligible to participate four weeks after completing their treatment (wash-out period).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Bonafide Sleep Supplement on Sleep Parameters in Menopausal Women With Sleep Complaints: An Open-Label Experience Trial
This open-label study was designed to evaluate whether a daily dietary sleep supplement could improve sleep quality and related daytime well-being in menopausal women aged 40 to 65 with sleep complaints. All participants received the study supplement for approximately 12 weeks, followed by a four-week period without the supplement to assess changes after discontinuation. Sleep quality, sleep and well-being complaints, product experience, safety, and tolerability were assessed throughout the study.
Read the detailed description
This is an open-label, single-group clinical trial conducted to evaluate the effects of a dietary sleep supplement on subjective sleep quality and related well-being in perimenopausal and postmenopausal women with sleep complaints. The study was designed to enroll approximately 150 women aged 40 to 65 from across the United States. All participants received the study supplement, and all study procedures were conducted remotely.
Following electronic informed consent, participants completed a screening phase conducted via virtual visit, during which medical history, sleep complaints, and eligibility criteria were assessed. Eligible participants then entered a run-in period of approximately seven days to familiarize themselves with study procedures. No study product was consumed during the run-in period.
After completion of the run-in period, participants initiated the intervention on Day 1 and self-administered the study product once daily through approximately Day 85. The study product was administered orally as two tablets approximately 60 minutes before bedtime. Participants continued supplementation for approximately 12 weeks through the End of Intervention visit.
Throughout the intervention period, participants completed electronic questionnaires assessing sleep quality and related sleep and well-being complaints. Sleep quality was assessed regularly using visual analog scales, and sleep and well-being complaints were assessed at protocol-defined intervals. Participant experience with the study product was also evaluated near the end of the intervention period.
Following completion of the intervention period, participants discontinued the study product and entered a washout period from approximately Day 86 through Day 113. Study assessments continued during this period to characterize changes following discontinuation, and participants completed a washout questionnaire at the End of Study visit.
All study visits and assessments were conducted remotely through virtual or telephone visits. Safety and tolerability were monitored throughout participation through participant reporting and scheduled study contacts. Each participant's total duration of participation was approximately 18 to 19 weeks, including screening, run-in, intervention, washout, and end-of-study assessments.
- Conditions
- Sleep Disturbance
- Being tested
- S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
- Keywords
- Menopause, Perimenopause, Postmenopause, Sleep Complaints, Sleep Disturbance, Sleep Quality, Sleep Onset Latency, Sleep Maintenance, Daytime Sleepiness, Morning Grogginess, Deep Sleep, Quality of Life, Women's Health
- Medical subject headings
- Parasomnias, Sleep Initiation and Maintenance Disorders, Disorders of Excessive Somnolence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium GlycinateDietary supplement
Also called Bonafide Sleep
A daily dietary sleep supplement taken once per day for 85 days.
| Study group | Role | What they receive |
|---|---|---|
| Bonafide Sleep | Experimental | Participants received Bonafide Sleep orally as two tablets once daily approximately 60 minutes before bedtime from Day 1 through Day 85. After the intervention period, participants discontinued the study product and entered a washout period through Day 113. Receives: Dietary Supplement: S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Morning Ease as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported difficulty leaving bed and beginning the day, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no difficulty, while a score of 100 indicates extreme difficulty that is nearly impossible to overcome. Lower scores indicate greater ease beginning the day.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Sleep-Onset Latency as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported time required to fall asleep, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates falling asleep almost immediately, while a score of 100 indicates substantial difficulty falling asleep. Lower scores indicate easier sleep initiation.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Sleep Disturbances as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported frequency of sleep disturbances measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no sleep disturbances and peaceful sleep every night, while a score of 100 indicates constant sleep disturbances every night. Lower scores indicate fewer sleep disturbances.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Wakefulness After Sleep Onset (WASO) as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported difficulty returning to sleep after awakening during the night, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no nighttime awakening, while a score of 100 indicates finding it very difficult or impossible to fall back asleep. Lower scores indicate better sleep maintenance.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Mental Confusion as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported mental confusion upon waking, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no mental confusion and clear, focused thoughts, while a score of 100 indicates intense mental confusion and substantial difficulty achieving clarity. Lower scores indicate less mental confusion.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Morning Grogginess as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported morning grogginess measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no grogginess and feeling fully alert upon waking, while a score of 100 indicates intense morning grogginess with marked drowsiness and lethargy. Lower scores indicate less morning grogginess.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Restfulness or Rejuvenation as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported restfulness or rejuvenation upon waking, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates feeling fully rested and rejuvenated, while a score of 100 indicates no sense of restfulness or rejuvenation. Lower scores indicate greater restfulness.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Deep Sleep as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported experience of deep, restorative sleep measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates consistently experiencing deep, uninterrupted, restorative sleep, while a score of 100 indicates experiencing no perceived deep sleep. Lower scores indicate greater perceived deep sleep.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Daytime Sleepiness as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported daytime sleepiness measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates feeling alert and energetic without daytime sleepiness, while a score of 100 indicates an overpowering urge to sleep or nap. Lower scores indicate less daytime sleepiness.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Sleep Satisfaction as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported satisfaction with sleep measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates being extremely satisfied with sleep, while a score of 100 indicates being extremely dissatisfied. Lower scores indicate greater sleep satisfaction.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Sleep Quality as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported overall sleep quality measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates excellent sleep quality, while a score of 100 indicates extremely poor sleep quality. Lower scores indicate better sleep quality.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Overall Quality of Life as Measured by a Visual Analog Scale (VAS)
Change from baseline in self-reported overall quality of life measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates excellent quality of life and complete satisfaction, while a score of 100 indicates extremely poor quality of life and no satisfaction. Lower scores indicate better perceived quality of life.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change in Sleep and Well-Being Complaints Questionnaire Responses
Change from baseline in participant-reported sleep and well-being complaints. The questionnaire assesses sleep initiation and latency, sleep maintenance and quality, morning refreshment and energy, daytime functioning and cognitive clarity, and emotional and physical well-being. Individual complaints are assessed as present or absent, with severity rated from 0 to 100 when a complaint is endorsed.
Measured: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 28 days
Participant Experience With the Study Product
Participant responses to the Product Experience Questionnaire assessing overall satisfaction with the study product, ease of use, perceived effects on sleep and daytime functioning, overall product experience, and willingness to recommend or continue using the product. Scored Likert items range from 1 (Strongly Disagree) to 4 (Strongly Agree), with higher scores indicating a more favorable product experience. Selected items include 0 = Not Applicable, which is not treated as a scored response. Additional items use Yes/No/Not Applicable or open-text responses. No composite total score is calculated; responses are summarized by individual item.
Measured: Week 12 (Day 85 ± 3 days) and Week 16 (Day 113 ± 3 days)
Participant-Reported Changes Following Study Product Discontinuation
Participant responses to the Washout Questionnaire assessing perceived changes following discontinuation of the study product, including sleep quality, daytime restfulness and energy, cognitive function, mood, overall satisfaction, perceived product benefit, and likelihood of recommending the product. The questionnaire uses item-specific ordered categorical response options, including 4-level responses (e.g., Very Dissatisfied to Very Satisfied; Strongly Disagree to Strongly Agree) and 5-level responses (e.g., Not Effective to Very Effective; Much Worse to Much Better; Definitely Not to Definitely Yes). More favorable response categories indicate a more favorable perceived outcome. No composite total score or single minimum/maximum questionnaire score is calculated; responses are summarized by individual item.
Measured: Week 16 (Day 113 ±3 days), following approximately 4 weeks of study product discontinuation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start3 Jan 2025
- Primary completion1 Jul 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep DisturbanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single-group, open-label study in which all participants received the investigational dietary sleep supplement during the intervention period, followed by a post-intervention washout period.
- Masking
- None (open label)
- Enrolment
- 111 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bonafide Health
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Trisha VanDusseldorp, PhD, Principal investigator, Bonafide Health, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07839312
- Sponsor's protocol ID
- Pro00083360
- Status last verified
- Sep 2026
- First submitted
- 15 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Bonafide Sleep Supplement on Sleep Parameters in Menopausal Women With Sleep Complaints: An Open-Label Experience Trial
- ClinicalTrials.gov ID
- NCT07839312
- Acronym / sponsor ID
- Pro00083360
- Conditions
- Sleep Disturbance
- Keywords
- Menopause, Perimenopause, Postmenopause, Sleep Complaints, Sleep Disturbance, Sleep Quality, Sleep Onset Latency, Sleep Maintenance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 111 participants (actual)
- Lead sponsor
- Bonafide HealthIndustry (pharma, biotech, devices)
- Study start
- 3 Jan 2025 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label study was designed to evaluate whether a daily dietary sleep supplement could improve sleep quality and related daytime well-being in menopausal women aged 40 to 65 with sleep complaints. All participants received the study supplement for approximately 12 weeks, followed by a four-week period without the supplement to assess changes after discontinuation. Sleep quality, sleep and well-being complaints, product experience, safety, and tolerability were assessed throughout the study.
Detailed description
This is an open-label, single-group clinical trial conducted to evaluate the effects of a dietary sleep supplement on subjective sleep quality and related well-being in perimenopausal and postmenopausal women with sleep complaints. The study was designed to enroll approximately 150 women aged 40 to 65 from across the United States. All participants received the study supplement, and all study procedures were conducted remotely.
Following electronic informed consent, participants completed a screening phase conducted via virtual visit, during which medical history, sleep complaints, and eligibility criteria were assessed. Eligible participants then entered a run-in period of approximately seven days to familiarize themselves with study procedures. No study product was consumed during the run-in period.
After completion of the run-in period, participants initiated the intervention on Day 1 and self-administered the study product once daily through approximately Day 85. The study product was administered orally as two tablets approximately 60 minutes before bedtime. Participants continued supplementation for approximately 12 weeks through the End of Intervention visit.
Throughout the intervention period, participants completed electronic questionnaires assessing sleep quality and related sleep and well-being complaints. Sleep quality was assessed regularly using visual analog scales, and sleep and well-being complaints were assessed at protocol-defined intervals. Participant experience with the study product was also evaluated near the end of the intervention period.
Following completion of the intervention period, participants discontinued the study product and entered a washout period from approximately Day 86 through Day 113. Study assessments continued during this period to characterize changes following discontinuation, and participants completed a washout questionnaire at the End of Study visit.
All study visits and assessments were conducted remotely through virtual or telephone visits. Safety and tolerability were monitored throughout participation through participant reporting and scheduled study contacts. Each participant's total duration of participation was approximately 18 to 19 weeks, including screening, run-in, intervention, washout, and end-of-study assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single-group, open-label study in which all participants received the investigational dietary sleep supplement during the intervention period, followed by a post-intervention washout period.
| Arm | Type | Receives |
|---|---|---|
| Bonafide Sleep | Experimental | Dietary Supplement: S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium GlycinateParticipants received Bonafide Sleep orally as two tablets once daily approximately 60 minutes before bedtime from Day 1 through Day 85. After the intervention period, participants discontinued the study product and entered a washout period through Day 113. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Healthy women who are 40 to 65 years of age (inclusive).
- Have a body mass index (BMI) between 18.5 to 39.9 kg/m2 (inclusive).
- Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form (PROMIS SD SF) T-Score Cut Point ≥ 55 (equivalent to a raw score of 25).
- Women enrolled in this research study may be of perimenopausal, (12 or more months without a menstrual period) or post-menopausal status. Post-menopause defined as the last natural menstrual period (LNMP) completed at least 12 months prior to screening. Perimenopause defined as women who complained of irregular menstrual cycle in the past 12 months, with a forward or postponed cycle more than 7 days. At least 2 cycles were missing during the past 12 months or reported menopause for at least 60 days.
- In good general health (no uncontrolled diseases or conditions) and able to consume the study product.
Key exclusion criteria (10 listed)
- Individuals who are lactating, pregnant, or planning to become pregnant during the study.
- Perimenopausal women who are sexually active will be required to specify contraceptive method or be excluded.
- Currently incarcerated prisoners.
- Currently enrolled in a different clinical trial.
- Use of any treatment for sleep symptoms or other concomitant treatments listed in Section 12.4.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium GlycinateAlso: Bonafide SleepA daily dietary sleep supplement taken once per day for 85 days. | Dietary supplement | Bonafide Sleep |
Primary outcome
Change in Morning Ease as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported difficulty leaving bed and beginning the day, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no difficulty, while a score of 100 indicates extreme difficulty that is nearly impossible to overcome. Lower scores indicate greater ease beginning the day.
Change in Sleep-Onset Latency as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported time required to fall asleep, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates falling asleep almost immediately, while a score of 100 indicates substantial difficulty falling asleep. Lower scores indicate easier sleep initiation.
Change in Sleep Disturbances as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported frequency of sleep disturbances measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no sleep disturbances and peaceful sleep every night, while a score of 100 indicates constant sleep disturbances every night. Lower scores indicate fewer sleep disturbances.
Change in Wakefulness After Sleep Onset (WASO) as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported difficulty returning to sleep after awakening during the night, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no nighttime awakening, while a score of 100 indicates finding it very difficult or impossible to fall back asleep. Lower scores indicate better sleep maintenance.
Change in Mental Confusion as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported mental confusion upon waking, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no mental confusion and clear, focused thoughts, while a score of 100 indicates intense mental confusion and substantial difficulty achieving clarity. Lower scores indicate less mental confusion.
Change in Morning Grogginess as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported morning grogginess measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates no grogginess and feeling fully alert upon waking, while a score of 100 indicates intense morning grogginess with marked drowsiness and lethargy. Lower scores indicate less morning grogginess.
Change in Restfulness or Rejuvenation as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported restfulness or rejuvenation upon waking, measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates feeling fully rested and rejuvenated, while a score of 100 indicates no sense of restfulness or rejuvenation. Lower scores indicate greater restfulness.
Change in Deep Sleep as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported experience of deep, restorative sleep measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates consistently experiencing deep, uninterrupted, restorative sleep, while a score of 100 indicates experiencing no perceived deep sleep. Lower scores indicate greater perceived deep sleep.
Change in Daytime Sleepiness as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported daytime sleepiness measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates feeling alert and energetic without daytime sleepiness, while a score of 100 indicates an overpowering urge to sleep or nap. Lower scores indicate less daytime sleepiness.
Change in Sleep Satisfaction as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported satisfaction with sleep measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates being extremely satisfied with sleep, while a score of 100 indicates being extremely dissatisfied. Lower scores indicate greater sleep satisfaction.
Change in Sleep Quality as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported overall sleep quality measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates excellent sleep quality, while a score of 100 indicates extremely poor sleep quality. Lower scores indicate better sleep quality.
Change in Overall Quality of Life as Measured by a Visual Analog Scale (VAS)
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days
Change from baseline in self-reported overall quality of life measured using a visual analog scale (VAS) ranging from 0 to 100. A score of 0 indicates excellent quality of life and complete satisfaction, while a score of 100 indicates extremely poor quality of life and no satisfaction. Lower scores indicate better perceived quality of life.
Change in Sleep and Well-Being Complaints Questionnaire Responses
Time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 28 days
Change from baseline in participant-reported sleep and well-being complaints. The questionnaire assesses sleep initiation and latency, sleep maintenance and quality, morning refreshment and energy, daytime functioning and cognitive clarity, and emotional and physical well-being. Individual complaints are assessed as present or absent, with severity rated from 0 to 100 when a complaint is endorsed.
Participant Experience With the Study Product
Time frame: Week 12 (Day 85 ± 3 days) and Week 16 (Day 113 ± 3 days)
Participant responses to the Product Experience Questionnaire assessing overall satisfaction with the study product, ease of use, perceived effects on sleep and daytime functioning, overall product experience, and willingness to recommend or continue using the product. Scored Likert items range from 1 (Strongly Disagree) to 4 (Strongly Agree), with higher scores indicating a more favorable product experience. Selected items include 0 = Not Applicable, which is not treated as a scored response. Additional items use Yes/No/Not Applicable or open-text responses. No composite total score is calculated; responses are summarized by individual item.
Participant-Reported Changes Following Study Product Discontinuation
Time frame: Week 16 (Day 113 ±3 days), following approximately 4 weeks of study product discontinuation
Participant responses to the Washout Questionnaire assessing perceived changes following discontinuation of the study product, including sleep quality, daytime restfulness and energy, cognitive function, mood, overall satisfaction, perceived product benefit, and likelihood of recommending the product. The questionnaire uses item-specific ordered categorical response options, including 4-level responses (e.g., Very Dissatisfied to Very Satisfied; Strongly Disagree to Strongly Agree) and 5-level responses (e.g., Not Effective to Very Effective; Much Worse to Much Better; Definitely Not to Definitely Yes). More favorable response categories indicate a more favorable perceived outcome. No composite total score or single minimum/maximum questionnaire score is calculated; responses are summarized by individual item.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Sleep Disturbance
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Recruiting
Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity
Histamine, Cowhage
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Trisha VanDusseldorp, PhD principal investigator
Bonafide Health, LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate in people with Sleep Disturbance, run by Bonafide Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Morning Ease as Measured by a Visual Analog Scale (VAS) (time frame: Baseline (Day 1) through Week 16 (Day 113 ±3 days), assessed every 7 days). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.